Avantor Filed for a $100 million IPO on 3/15/19. The stock will trade on the NYSE under the symbol AVTR.
Avantor provides products and services to biopharma, nutraceutical, biomaterials and research/diagnostic segments in the life science arena. The company also serves additional industries such as aerospace, defense, commercial aviation, etc. Avantor combines innovation centers and manufacturing centers to serve customers from the earliest stages of product development to commercial manufacturing.
Avantor has been on a rapid growth trajectory. Net sales in 2018 are more than eight times 2016's The company's current growth strategy includes plans to increase integration of their products and services into customer’s workflows and expand into bioproduction ( serums, reagents, excipients, chromatography resins and single-use assemblies) among others.